- Research article
- Open Access
- Open Peer Review
Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas
© Lyng et al; licensee BioMed Central Ltd. 2007
- Received: 20 September 2006
- Accepted: 17 January 2007
- Published: 17 January 2007
High-resolution magic angle proton magnetic resonance spectroscopy (HR 1H MAS MRS) provides a broad metabolic mapping of intact tumor samples and allows for microscopy investigations of the samples after spectra acquisition. Experimental studies have suggested that the method can be used for detection of apoptosis, but this has not been investigated in a clinical setting so far. We have explored this hypothesis in cervical cancers by searching for metabolites associated with apoptosis that were not influenced by other histopathological parameters like tumor load and tumor cell density.
Biopsies (n = 44) taken before and during radiotherapy in 23 patients were subjected to HR MAS MRS. A standard pulse-acquire spectrum provided information about lipids, and a spin-echo spectrum enabled detection of non-lipid metabolites in the lipid region of the spectra. Apoptotic cell density, tumor cell fraction, and tumor cell density were determined by histopathological analysis after spectra acquisition.
The apoptotic cell density correlated with the standard pulse-acquire spectra (p < 0.001), but not with the spin-echo spectra, showing that the lipid metabolites were most important. The combined information of all lipids contributed to the correlation, with a major contribution from the ratio of fatty acid -CH2 to CH3 (p = 0.02). In contrast, the spin-echo spectra contained the main information on tumor cell fraction and tumor cell density (p < 0.001), for which cholines, creatine, taurine, glucose, and lactate were most important. Significant correlations were found between tumor cell fraction and glucose concentration (p = 0.001) and between tumor cell density and glycerophosphocholine (GPC) concentration (p = 0.024) and ratio of GPC to choline (p < 0.001).
Our findings indicate that the apoptotic activity of cervical cancers can be assessed from the lipid metabolites in HR MAS MR spectra and that the HR MAS data may reveal novel information on the metabolic changes characteristic of apoptosis. These changes differed from those associated with tumor load and tumor cell density, suggesting an application of the method to explore the role of apoptosis in the course of the disease.
- Partial Less Square
- Partial Less Square Analysis
- Lipid Metabolite
- Tumor Cell Density
Apoptosis plays an important role in cancer development, progression, and response to therapy [1, 2]. Malignant cells have defects in cellular death pathways and therefore the ability to circumvent apoptosis and survive under abnormal conditions . Low apoptotic activity has been associated with aggressiveness and treatment resistance of many tumor types, including cervical carcinomas [4, 5]. Apoptosis is also an important mode of cell death after chemo- and radiotherapy, although its relative contribution to the overall cell death has not been clarified . Information on the apoptotic activity in tumors and the metabolic changes involved may give valuable insight into the mechanisms underlying cancer progression and treatment response. Considerable effort is therefore put into the development of clinically useful methods for detection and exploration of apoptosis.
MR spectroscopy allows for a broad metabolic mapping of tissues at the molecular level that may be used to investigate the balance between cell death and survival . Detailed biochemical characterization of hundreds of metabolites is provided in a single experiment, yielding specific information on the turnover of lipids, carbohydrates, and polypeptides . Experimental studies, both in vivo and based on tissue extracts, have indicated a potential of the method to detect apoptosis from the levels of cholines and fatty acids [8, 9]. Recent developments by utilization of the HR MAS technique have enabled production of high quality spectra from intact tissues without the artefacts introduced by extraction procedures . Histological studies can be performed on the samples after spectrum acquisition, yielding information on the underlying causes of the metabolic data.
There is currently a large interest in exploring the clinical potential of HR MAS MRS. Several studies have shown that malignant lesions can be distinguished from benign ones in the spectra [11–16], and utilizations of the method for prediction of tumor aggressiveness and treatment outcome have been proposed [12, 14, 15]. Only a few HR MAS studies have investigated the relationship between apoptosis and spectral data [17–20]. The studies are based on rat gliomas with high apoptotic activity and homogeneous tissue composition compared to human tumors. Normal cells within the tumor contribute significantly to the MR signals and increase the complexity of clinical data. The proportion of malignant cells and their apoptotic activity may be interrelated, necessitating identification of spectral characteristics of apoptosis that differ from those associated with tumor load and tumor cell density. The clinical relevance of the previous findings is therefore not clear.
The present work was conducted to explore the utilization of HR MAS MRS for detection of apoptosis in cervical cancers. Spectral characteristics specific for apoptotic cell density, tumor cell fraction, and tumor cell density, as determined by histopathologic analysis of the samples after spectrum acquisition, were searched for. Biopsies taken before the start of treatment and after one week of therapy were included to achieve a broad, but clinically relevant, range of the histopathologic parameters. Significant relationships between the HR MAS MR spectra and the histopathology were found and metabolites specific for apoptosis that were clearly distinguished from those associated with tumor cell fraction and tumor cell density were identified.
Patients and tumor samples
Twenty-three patients with primary squamous cell carcinoma of the uterine cervix were included. Tumor stage (The Fédération Internationale des Gynaecologistes et Obstetristes) was 1b (1 patient), 2b (16), and 3b (6). All patients were treated with curative intent. Radiotherapy was given to all but one patient, who received surgery. External irradiation, a total of 50 Gy to tumor and parametria and 45 Gy to the rest of the pelvic region, was given in fractions of 2 and 1.8 Gy, respectively. Brachytherapy, 21 Gy in five fractions, was thereafter employed. Nineteen patients received adjuvant cisplatin (40 mg/m2) weekly during the period of external radiation, starting the same day as the radiotherapy. The study was approved by the local ethical committee, and written informed-consent was obtained from all patients.
Tumor biopsies, 5 × 5 × 5 mm in size, were taken before the start of treatment from all twenty-three patients and after 1 week (10 Gy) of external radiotherapy from twenty patients. Two pre-treatment biopsies were included for one of the patients, leading to a total of 44 samples. Efforts were made to select samples from the viable tumor tissue, avoiding necrotic regions that were sometimes visible particularly after 1 week of therapy. The biopsies were immediately frozen in liquid nitrogen and stored at -80°C until MR analysis.
The samples were cut to fit a MAS rotor (50 μL, mean sample weight 16.2 mg), and added phosphate buffered saline made up in D2O with trimethylsilyl propionic acid (TSP, 1.4 mM) as a chemical shift reference and standard for quantification of metabolites. HR MAS experiments were performed on a Bruker Avance DRX600 spectrometer equipped with a 1H/13C MAS probe with gradient aligned with the magic angle axis (Bruker BioSpin GmbH, Germany), as reported earlier . Samples were spun at 5 kHz at an instrumental temperature setting of 4°C. Two spectra were recorded for each sample. A standard pulse-acquire spectrum with suppression of water signal (zgpr; BRUKER) allowed for quantification of metabolite concentrations and provided information on lipid metabolites, whereas a spin-echo spectrum with suppression of both water and lipid signal (cpmgpr; BRUKER) enabled detection of non-lipid metabolites in the spectral region of the lipids. The standard pulse-acquire experiments included a 60° flip angle over a spectral region of 20.0 ppm after 3.0 sec of water presaturation. The free induction decay (FID) was acquired into 64 K points during 2.72 sec, and 32 transients were collected. The spin-echo experiments were performed using 2 sec of water suppression prior to a 90 degrees excitation pulse. A total of 128 transients over a spectral region of 16.7 ppm were collected into 32 K points during 1.64 sec. The T2-filtering was obtained using a delay of 1 ms repeated 136 times, resulting in 285 ms effective echo time. The repetition time was 3.93 sec. Spectral assignments were performed based on our previous HR MAS study of cervical cancers . The samples were fixed in formalin after the MR experiment. A time period of 30 min was used for spectrum acquisition, and the mean period from the start of the experiment to fixation was 1 hour 55 min. The FIDs were Fourier transformed after 0.3 Hz exponential line broadening, and the phase was manually corrected. A linear baseline correction was applied. Chemical shifts were referenced to the TSP peak at 0 ppm.
The samples were embedded in paraffin casts. A 5 μm thick section from the middle part of each biopsy was subjected to histological analysis for determination of apoptotic cell density, tumor cell fraction, and tumor cell density, as described previously , assuming that the data of this section were representative for the entire biopsy. One biopsy contained solely necrosis. Stroma and tumor cells, but no necrosis, were seen in the others. Since necrosis most often affects many adjacent cells at the same time and is easily visible in the microscope, the proportion of necrosis was assumed to be zero in the latter biopsies. In contrast, apoptosis may often occur in single cells spread throughout the tissue.
To detect the apoptotic cells, the sections were stained by use of the Apotag in situ apoptosis detection kit (Oncor, Gaithersburg, MD), which is based on the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling (TUNEL) method. Slide preparation and staining were performed as described by the manufacturer. A biopsy from a neoplastic lymph node of a patient with B-cell non-Hodgkin's lymphoma served as a positive control, whereas negative controls received no TdT. Apoptotic cell density was defined as the number of apoptotic tumor cells per mm2 of tissue (including stroma and tumor tissue), and was calculated as:
A t = F c ·A c (1)
where A t is apoptotic cell density, F c is tumor cell fraction, and A c is number of apoptotic nuclei per mm2 of tumor tissue. F c was determined in hematoxylin and eosin (HE) stained sections by point counting at a magnification of 100×, and A c was determined by counting all apoptotic cells within the tumor tissue at high magnification (400×).
Tumor cell density, defined as number of tumor cell nuclei per mm2 of tissue (including stroma and tumor tissue), was calculated as:
D t = F c ·D c (2)
where D t is tumor cell density, F c is tumor cell fraction, and D c is number of nuclei per mm2 of tumor tissue. D c was determined in HE stained sections by counting all nuclei within selected fields in the tumor tissue at high magnification (400×).
Apoptotic cell density, tumor cell fraction and tumor cell density were also determined in nine samples that had not been subjected to MR examinations. These data were compared to the data of the HR MAS samples, to search for systematic changes in the histopathology caused by the MR experiement. The samples were prepared and analysed as described above.
Partial least square regression (PLS)
The MR spectra and histopathological parameters were analysed by PLS to identify the metabolites that were most strongly related to apoptotic cell density, tumor cell fraction, and tumor cell density. The analysis relates variations in one or several dependent variables; i.e, the histopathological parameters, to the variations of several independent variables; i.e., the spectral data, with explanatory or predictive purposes. The method performs well when the independent variables are collinear, which can be expected with MR data. The information in the original MR spectra was projected onto a number of principal components (PCs). The histolopathological parameters were actively used in estimating the PCs, ensuring that the first PCs were those that were most relevant for predicting the parameter.
The MR spectra were converted to ASCII-format, peak aligned according to a recently reported algorithm [22, 23], and imported into the Unscrambler package (CAMO process AS, Norway) for PLS analysis. The region between 0.7 and 2.2 ppm, mainly containing broad resonances from lipids with signals from the fatty acid protons - CH3 (0.9 ppm), - (CH2)n (1.3 ppm), - CH2 - CH3 (1.35 ppm), - CH2 - CH2 - CO (1.58 ppm), - CH = CH - CH2 - CH2 (2.02 ppm), was used in the standard spectra. The ethanol triplet at 1.19 ppm that occurred due to the laboratory sterilizing procedure, was excluded. In the spin-echo spectra the regions containing the peaks for glucose, lactate, myo-inositol, taurine, glycerophosphocholine (GPC), phosphocholine (PC) choline, and creatine were selected for further analysis. Baseline offset was adjusted, and the spectra were scaled by mean normalisation; i.e., the area below the curve was made equal for all spectra. PLS calibration of apoptotic cell density, tumor cell fraction, and tumor cell density to the spectral variables was performed in separate runs. The model calibrations were performed with mean centered data; i.e., the average of each variable subtracted from each of the data values in the variable. This centering means that the results can be interpreted in terms of deviations from the average. Full cross-validation (leave-one-out) was applied in model calibration. The number of PCs to retain in the model was determined by finding the principal component where total residual y-variance and root mean square error of prediction were minimised. Loading profiles of the principal components were generated to visualize the relative contribution of the metabolites to the model. Pearson correlation analysis was used to find the correlation between the predicted and measured parameter.
Estimation of metabolite concentrations
To further explore the association between metabolites and histopathology, correlation analyses based on individual metabolite concentrations and metabolite ratios were performed. The concentrations were calculated for β-glucose, GPC, PC, choline, creatine, lactate, fatty acid -CH2 (1.3 ppm), fatty acid -CH3 (0.9 ppm), and TSP from the standard pulse-acquire spectra, as described previously . The spectral regions 4.6 to 4.7 ppm (β-glucose), 3.4 to 2.9 ppm (GPC, PC, choline, and creatine), 1.8 to 0.5 ppm (lipids and lactate), and -0.1 to 0.1 ppm (TSP) were individually baseline corrected, using a linear function. Peak areas were calculated using combined Lorentzian and Gaussian line functions (Voigt area) in a curve-fitting program (PeakFit, Systat Software Inc., Richmond, CA). The correlation coefficient, r, of the fit was 0.95 or larger for all area calculations. The peak area of the metabolite relative to the area of the internal standard TSP and sample wet weight was used as a measure of metabolite concentration. The concentrations were related to the histopathological parameters by use of Pearson correlation analysis and the SPSS software.
Histopathology and spectral characteristics
Relationships between histopathology and spectral profiles
Relationships between histopathology, metabolite concentrations, and metabolite ratios
Correlations between HR MAS MR metabolites and histopathology of cervical carcinomas
Apoptotic cell density
Tumor cell fraction
Tumor cell density
Detailed characterization of intact samples from cervical carcinomas by use of HR MAS MRS enabled identification of metabolites associated with apoptotic cell density, tumor cell fraction, and tumor cell density in our study. We showed that the samples were well preserved and that no apoptosis or cell death was induced during spectrum acquisition, in accordance with recent studies showing stable expression of apoptosis promoting genes during the experiment . These findings justified direct correlation studies between MR data and histopathology and exploration of the underlying causes of the spectral profiles. Metabolites that were characteristic of apoptosis and differed from those associated with tumor cell fraction and tumor cell density were identified. The strongest relationship to the histopathology was achieved by including the spectral profiles of several metabolites in the analyses, showing that the combined metabolic information was important.
Apoptotic cell density correlated with the standard pulse-acquire spectra but not with the spin-echo profiles, suggesting that the lipid region contained the major information on apoptosis. In agreement with this hypothesis, the ratio of fatty acid - CH2 to - CH3, but none of the choline-containing metabolites, creatine, taurine, glucose, or lactate, was associated with apoptosis when individual metabolites and metabolite ratios were considered. Similar relationships between fatty acid -CH2 to -CH3 and apoptosis have also been reported in MR spectroscopy studies on Jurkat T-cell cultures treated with doxorubicin . A weaker correlation was, however, found in our study probably because of the smaller range of apoptotic cell densities. The elevated -CH2 to -CH3 ratio in highly apoptotic tissues indicates increased fatty acid -CH2 chain length and/or increased degree of fatty acid saturation as apoptosis develops. The cause of this observation is not known, both dynamic and/or compositional changes in the plasma membrane and in cytoplasmic lipid droplets have been proposed . The fatty acid - CH2 to -CH3 ratio was not significantly influenced by tumor cell fraction or tumor cell density in our study, but reflected the apoptotic activity per se, suggesting that this ratio can be used as an independent measure of apoptosis in cervical carcinomas.
Spectral characteristics associated with tumor cell fraction and tumor cell density were found in the region above 3 ppm. Choline, PC, and GPC were major metabolites contributing to the correlation in both cases, as verified from the loading profiles in the PLS analysis. High levels of GPC and PC and low levels of choline indicate activation of the phosphatidylcholine pathway and consequently a high membrane turnover and/or activation of cell proliferation and survival signalling [24, 25], consistent with a high tumor cell fraction or tumor cell density. Up-regulation of the choline transport through the activation of choline kinase, leading to the observed changes in the choline metabolites, have been reported for many tumor types and is thought to be a common feature of cancers . GPC concentration and GPC to choline ratio correlated with the tumor cell density in analysis of individual metabolites and ratios, whereas tumor cell fraction showed no such correlation, probably reflecting the cellular rather than extracellular localization of these metabolites and therefore a major dependence on the number of cells in the sample. Choline-containing metabolites have previously been shown to distinguish carcinomas and liposarcomas from non-cancerous tissue in HR MAS spectra [11–16]. Our results suggest a quantitative utilization of these data to assess tumor cell density in cervical cancer samples.
Creatine, taurine, glucose, and lactate also contributed to the strong correlation between the spectral profiles and tumor cell fraction and tumor cell density. Increased levels of creatine and taurine have been observed in HR MAS spectra of breast cancers as compared to non-malignant tissue , consistent with our results. The mechanisms underlying these findings have not been clarified, since taurine appears to have different functions in different tissues . In contrast, the glucose and lactate data could be explained from nutrient depletion and increased anaerobe metabolism in cervical tumors as compared to normal tissues [28, 29]. The MR signals of these metabolites originate from both the extracellular and cellular compartments , probably explaining the stronger relationship to tumor cell fraction than to tumor cell density. We have previously reported low glucose level in HR MAS spectra of cervical carcinomas as compared to normal samples . Our present results indicate that this level can be a quantitative marker of tumor cell fraction in the carcinoma samples.
It was assumed that the spectral changes in lipid metabolites were caused solely by apoptosis, and not necrosis, in our work. Previous studies have shown that necrosis also may lead to changes in these metabolites . It cannot be excluded that minor extent of necrosis was present in the samples, although not detected in analyses, and influenced the results. The only necrotic sample identified had spectral characteristics that resembled the highly apoptotic tissues with respect to lipid metabolites and tissues with low tumor cell density with respect to GPC concentration and ratio of GPC to choline. Further investigations, including both necrotic and apoptotic tissues, are therefore needed to clarify whether the two modes of cell death can be distinguished in the spectra or if the elevated fatty acid -CH2 to -CH3 ratio can be used as a measure of cell death in general.
Our studies showed that the apoptotic activity of cervical carcinomas was associated with the lipid metabolites in HR MAS MR spectra, whereas tumor cell fraction and tumor cell density were related to cholines, creatine, taurine, glucose, and lactate. This suggests that HR MAS MRS may be used to explore the role of apoptosis in the course of the malignant disease and to achieve increased insight into the metabolic changes that occur during growth and apoptosis development. The spectral information specific of tumor load and tumor cell density allows for a more complete picture of the sample histopathology that is needed for a proper interpretation of the apoptosis data. Our results also indicate that HR MAS MRS may be utilized for monitoring of the therapeutic response of cervical carcinomas through the detection of treatment induced cell death. The detailed information on changes in apoptosis, tumor cell fraction, and tumor cell density that can be achieved by metabolic mapping of biopsies taken at different time points throughout the treatment would be useful in judgement of the therapeutic effect.
We thank the staff at Department of Pathology, Rikshospitalet- Radiumhospitalet Medical Center, for preparing the histological sections and contributing to the histopathological evaluation. The work was sponsored by the Norwegian Women's Public Health Association, Trondheim, Norway, and Kreftfondet (Cancer Fund), St. Olavs University Hospital, Trondheim, Norway.
- Lowe SW, Lin AW: Apoptosis in cancer. Carcinogenesis. 2000, 21: 485-495. 10.1093/carcin/21.3.485.View ArticlePubMedGoogle Scholar
- Schmitt CA, Lowe SW: Apoptosis and therapy. J Pathol. 1999, 187: 127-137. 10.1002/(SICI)1096-9896(199901)187:1<127::AID-PATH251>3.0.CO;2-T.View ArticlePubMedGoogle Scholar
- Okada H, Mak TW: Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004, 4: 592-603. 10.1038/nrc1412.View ArticlePubMedGoogle Scholar
- Hockel M, Schlenger K, Hockel S, Vaupel P: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999, 59: 4525-4528.PubMedGoogle Scholar
- Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, Inazawa J: Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res. 2002, 62: 4860-4866.PubMedGoogle Scholar
- Hakumaki JM, Kauppinen RA: 1H NMR visible lipids in the life and death of cells. Trends Biochem Sci. 2000, 25: 357-362. 10.1016/S0968-0004(00)01614-5.View ArticlePubMedGoogle Scholar
- Ross BD: The biochemistry of living tissues: examination by MRS. NMR Biomed. 1992, 5: 215-219.View ArticlePubMedGoogle Scholar
- Blankenberg FG, Katsikis PD, Storrs RW, Beaulieu C, Spielman D, Chen JY, Naumovski L, Tait JF: Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood. 1997, 89: 3778-3786.PubMedGoogle Scholar
- Hakumaki JM, Poptani H, Sandmair AM, Yla-Herttuala S, Kauppinen RA: 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat Med. 1999, 5: 1323-1327. 10.1038/15279.View ArticlePubMedGoogle Scholar
- Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, Gonzalez RG: Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA. 1997, 94: 6408-6413. 10.1073/pnas.94.12.6408.View ArticlePubMedPubMed CentralGoogle Scholar
- Mahon MM, deSouza NM, Dina R, Soutter WP, McIndoe GA, Williams AD, Cox IJ: Preinvasive and invasive cervical cancer: an ex vivo proton magic angle spinning magnetic resonance spectroscopy study. NMR Biomed. 2004, 17: 144-153. 10.1002/nbm.869.View ArticlePubMedGoogle Scholar
- Millis K, Weybright P, Campbell N, Fletcher JA, Fletcher CD, Cory DG, Singer S: Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magn Reson Med. 1999, 41: 257-267. 10.1002/(SICI)1522-2594(199902)41:2<257::AID-MRM8>3.0.CO;2-N.View ArticlePubMedGoogle Scholar
- Sitter B, Bathen T, Hagen B, Arentz C, Skjeldestad FE, Gribbestad IS: Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy. MAGMA. 2004, 16: 174-181. 10.1007/s10334-003-0025-5.View ArticlePubMedGoogle Scholar
- Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS: Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006, 19: 30-40. 10.1002/nbm.992.View ArticlePubMedGoogle Scholar
- Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J: Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med. 2003, 50: 944-954. 10.1002/mrm.10614.View ArticlePubMedGoogle Scholar
- Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K, Vigneron DB, Kurhanewicz J: Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med. 2006, 55: 1257-1264. 10.1002/mrm.20909.View ArticlePubMedGoogle Scholar
- Griffin JL, Lehtimaki KK, Valonen PK, Grohn OH, Kettunen MI, Yla-Herttuala S, Pitkanen A, Nicholson JK, Kauppinen RA: Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. Cancer Res. 2003, 63: 3195-3201.PubMedGoogle Scholar
- Griffin JL, Blenkiron C, Valonen PK, Caldas C, Kauppinen RA: High-resolution magic angle spinning 1H NMR spectroscopy and reverse transcription-PCR analysis of apoptosis in a rat glioma. Anal Chem. 2006, 78: 1546-1552. 10.1021/ac051418o.View ArticlePubMedGoogle Scholar
- Lehtimaki KK, Valonen PK, Griffin JL, Vaisanen TH, Grohn OH, Kettunen MI, Vepsalainen J, Yla-Herttuala S, Nicholson J, Kauppinen RA: Metabolite changes in BT4C rat gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death as studied by 1H NMR spectroscopy in vivo, ex vivo, and in vitro. J Biol Chem. 2003, 278: 45915-45923. 10.1074/jbc.M306209200.View ArticlePubMedGoogle Scholar
- Valonen PK, Griffin JL, Lehtimaki KK, Liimatainen T, Nicholson JK, Grohn OH, Kauppinen RA: High-resolution magic-angle-spinning 1H NMR spectroscopy reveals different responses in choline-containing metabolites upon gene therapy-induced programmed cell death in rat brain glioma. NMR Biomed. 2005, 18: 252-259. 10.1002/nbm.955.View ArticlePubMedGoogle Scholar
- Lyng H, Sundfor K, Rofstad EK: Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis. Int J Radiat Oncol Biol Phys. 2000, 46: 935-946. 10.1016/S0360-3016(99)00497-6.View ArticlePubMedGoogle Scholar
- Forshed J, Schuppe-Koistinen I, Jacobsson SP: Peak alignment of NMR signals by means of genetic algorithm. Anal Chim Acta. 2003, 487: 189-199. 10.1016/S0003-2670(03)00570-1.View ArticleGoogle Scholar
- Lee GC, Woodruff DL: Beam search for peak alignment of NMR signals. Anal Chim Acta. 2004, 513: 413-416. 10.1016/j.aca.2004.02.068.View ArticleGoogle Scholar
- Podo F: Tumour phospholipid metabolism. NMR Biomed. 1999, 12: 413-439. 10.1002/(SICI)1099-1492(199911)12:7<413::AID-NBM587>3.0.CO;2-U.View ArticlePubMedGoogle Scholar
- Foster DA, Xu L: Phospholipase D in cell proliferation and cancer. Mol Cancer Res. 2003, 1: 789-800.PubMedGoogle Scholar
- Ackerstaff E, Glunde K, Bhujwalla ZM: Choline phospholipid metabolism: A target in cancer cells?. J Cell Biochem. 2003, 90: 525-533. 10.1002/jcb.10659.View ArticlePubMedGoogle Scholar
- Stapleton PP, O'Flaherty L, Redmond HP, Bouchier-Hayes DJ: Host defense – a role for the amino acid taurine?. J Parenter Enteral Nutr. 1998, 22: 42-48.View ArticleGoogle Scholar
- Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, Mueller-Klieser W: High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000, 60: 916-921.PubMedGoogle Scholar
- Walenta S, Mueller-Klieser WF: Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol. 2004, 14: 267-274. 10.1016/j.semradonc.2004.04.004.View ArticlePubMedGoogle Scholar
- Kuesel AC, Sutherland GR, Halliday W, Smith IC: 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed. 1994, 7: 149-155.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/7/11/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.